Amicar

Amicar is the brand name for the medication aminocaproic acid, an antifibrinolytic agent used to prevent and control bleeding. By inhibiting the activity of plasmin, it reduces the breakdown of fibrin clots and helps stabilize clots that have formed in conditions where excessive fibrinolysis contributes to bleeding.

Medical use and indications

Aminocaproic acid is used to treat or prevent bleeding in settings where fibrinolysis is unusually active. It is commonly employed to reduce bleeding during dental procedures in patients with bleeding disorders such as hemophilia, and it may be used in certain surgical, obstetric, and trauma-related contexts where hyperfibrinolysis is a concern. It can be given orally or by intravenous administration, and dosing is regimen-specific, guided by clinical judgment and product labeling.

Administration and pharmacology

Amicar is available in oral and injectable forms. It is absorbed when taken by mouth and is excreted primarily unchanged in the urine, necessitating dose adjustments in patients with impaired renal function. The intravenous route allows rapid onset of action in acute bleeding scenarios. Clinicians tailor dosing to the individual situation and monitor for efficacy and adverse effects. Rapid IV administration should be avoided to minimize risks.

Side effects and contraindications

Common adverse effects include nausea, vomiting, diarrhea, abdominal cramps, dizziness, and headaches. Thromboembolic events, hypersensitivity reactions, and other serious effects can occur, though they are less common. Contraindications include active intravascular clotting disorders, thromboembolic disease, known hypersensitivity to aminocaproic acid, and severe renal impairment without medical supervision. Safety in pregnancy and lactation should be evaluated on a case-by-case basis.

See also

Tranexamic acid, another antifibrinolytic agent used to reduce bleeding in similar contexts.